What KalVista Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 42 |
| Total trades | 0 | 91 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 428,977 |
| Disposed | 0 | 1,325,645 |
| Net activity | +0 | −896,668 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Palleiko Ben | CHIEF EXECUTIVE OFFICER | Jun 11 | Disposition to Issuer · D | −479,989 | — | — | 0 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | Jun 11 | Disposition to Issuer · D | −229,918 | — | — | 0 |
| Piekos Brian | Chief Financial Officer | Jun 11 | Disposition to Issuer · D | −21,661 | — | — | 0 |
| Sweeny Nicole | Chief Commercial Officer | Jun 11 | Disposition to Issuer · D | −59,291 | — | — | 0 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | Jun 11 | Disposition to Issuer · D | −150,260 | — | — | 0 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | May 27 | Open-market sale · S | −33,800 | $26.78 | −$905K | 229,918 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | May 27 | Exercise / conversion · M | +33,800 | $7.07 | +$239K | 263,718 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | May 26 | Open-market sale · S | −1,966 | $26.78 | −$52.6K | 229,918 |
| Sweeny Nicole | Chief Commercial Officer | May 26 | Open-market sale · S | −1,489 | $26.78 | −$39.9K | 59,291 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | May 26 | Open-market sale · S | −2,239 | $26.78 | −$60K | 150,260 |
| Palleiko Ben | CHIEF EXECUTIVE OFFICER | May 22 | Open-market sale · S | −10,926 | $26.78 | −$293K | 479,989 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | May 22 | Open-market sale · S | −2,358 | $26.78 | −$63.2K | 228,759 |
| Piekos Brian | Chief Financial Officer | May 22 | Open-market sale · S | −1,489 | $26.78 | −$39.9K | 21,661 |
| Sweeny Nicole | Chief Commercial Officer | May 22 | Open-market sale · S | −1,861 | $26.78 | −$49.8K | 55,780 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | May 22 | Open-market sale · S | −2,685 | $26.78 | −$71.9K | 147,499 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | May 22 | Exercise / conversion · M | +3,125 | — | — | 231,884 |
| Sweeny Nicole | Chief Commercial Officer | May 22 | Exercise / conversion · M | +5,000 | — | — | 60,780 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | May 22 | Exercise / conversion · M | +5,000 | — | — | 152,499 |
| Palleiko Ben | CHIEF EXECUTIVE OFFICER | May 21 | Exercise / conversion · M | +23,250 | — | — | 490,915 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | May 21 | Exercise / conversion · M | +3,750 | — | — | 231,117 |
Loading...
